Concepedia

Eric Vangrevelinghe

EV

27

Publications

1.7K

Citations

22

H-Index

2000

Active since

Affiliations

Novartis (Switzerland)(Current)

Novartis Institutes for BioMedical Research

Novartis (United States)

Dana-Farber Cancer Institute

Genomics Institute of the Novartis Research Foundation

Eric Vangrevelinghe is an author at Novartis (Switzerland) specializing in medicine, pharmacology, and drug discovery.

ORCID

Top concepts

Publications per year

2000–2024

27

Publications

27

Discovery of a Potent and Selective Protein Kinase CK2 Inhibitor by High-Throughput Docking

Eric Vangrevelinghe, Kaspar Zimmermann, Joseph Schoepfer et al. · Journal of Medicinal Chemistry · 2003 · 215 citations

, , +15

A Small-Molecule Dengue Virus Entry Inhibitor

Qingyin Wang, Sejal Patel, Eric Vangrevelinghe et al. · Antimicrobial Agents and Chemotherapy · 2009 · 206 citations · Full text

Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition

Oliver Weigert, Andrew A. Lane, Liat Bird et al. · The Journal of Experimental Medicine · 2012 · 161 citations · Full text

Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent

Rita Andraos, Zhiyan Qian, Débora Bonenfant et al. · Cancer Discovery · 2012 · 126 citations · Full text

, , +21

Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia

Shuo-Chieh Wu, Loretta S. Li, Nadja Kopp et al. · Cancer Cell · 2015 · 120 citations · Full text

, , +6

Rows per page

1–5 of 27